Releases


All 2013 Releases
May 30, 2013 Veloxis Pharmaceuticals A/S — annulment of warrants and registration of new Articles of Association pursuant thereto  
May 30, 2013 Veloxis Pharmaceuticals A/S — annullering af warrants og registrering af nye selskabsvedtægter i forlængelse deraf  
May 21, 2013 Det Europæiske Lægemiddelagentur starter behandling af Veloxis' ansøgning om markedsføringstilladelse for LCP-Tacro™ til behandling af nyretransplantationspatienter  
May 21, 2013 European Medicines Agency (EMA) Accepts Veloxis' Marketing Authorization Application (MAA) for LCP-Tacro for Treatment of Kidney Transplant Patients  
May 20, 2013 Final STRATO Clinical Study Data Demonstrates Potential for LCP-TacroTM to Improve Tacrolimus-Induced Tremors  
May 20, 2013 Endelige data fra det kliniske STRATO studie viser LCP-TacroTM's potentiale til forbedring af tacrolimus-induceret tremor (rysten)  
May 15, 2013 Veloxis Pharmaceuticals offentliggør finansielt resultat for de første 3 måneder af 2013  
May 15, 2013 Veloxis Pharmaceuticals announces financial results for the first three months of 2013  
May 7, 2013 Veloxis Pharmaceuticals A/S er vært for en telekonference i forbindelse med offentliggørelsen af kvartalsrapporten for 1. kvartal 2013 — resultater fra 1. januar til 31. marts 2013  
May 7, 2013 Veloxis Pharmaceuticals A/S to Host Conference Call Announcing Interim Report for first Quarter 2013 — results from 1 January to 31 March, 2013  
May 1, 2013 Nye vedtægter  
May 1, 2013 New Articles of Association  
Apr 29, 2013 Veloxis indsender ansøgning om markedsføringstilladelse (MAA) til Det Europæiske Lægemiddelagentur (EMA) for LCP-Tacro™ til behandling af nyreransplantationspatienter  
Apr 29, 2013 Veloxis Announces Submission of Marketing Authorization Application (MAA) to European Medicines Agency (EMA) for LCP-Tacro™ for Treatment of Kidney Transplant Patients  
Apr 17, 2013 Veloxis Pharmaceuticals A/S - Passing of Ordinary General Meeting  
Apr 17, 2013 Veloxis Pharmaceuticals A/S - Forløb af ordinær generalforsamling  
Mar 22, 2013 Indkaldelse til ordinær generalforsamling  
Mar 22, 2013 Notice to Convene Annual General Meeting  
Mar 6, 2013 Warrant Programme - Registration of capital increase and new Articles of Association following warrant exercise  
Mar 6, 2013 Warrant Program - Registrering af kapitalforhøjelse og nye selskabsvedtægter i forlængelse af warrantudnyttelse  
Mar 6, 2013 Warrant Programme - Veloxis Pharmaceuticals A/S issues new shares in connection with exercise of warrants and announces trading in the company's shares by executives  
Mar 6, 2013 Warrantprogram - Veloxis Pharmaceuticals A/S udsteder nye aktier i forbindelse med udnyttelse af warrants og indberetning af aktietransaktioner af ledende medarbejdere  
Mar 6, 2013 Veloxis Pharmaceuticals Annual Report 2012  
Mar 6, 2013 Veloxis Pharmaceuticals Årsrapport 2012  
Mar 6, 2013 Veloxis Pharmaceuticals publishes Annual Report 2012  
Mar 6, 2013 Veloxis Pharmaceuticals offentliggør årsrapport 2012  
Feb 27, 2013 Veloxis Pharmaceuticals A/S to Host Conference Call Announcing Annual report 2012  
Feb 27, 2013 Veloxis Pharmaceuticals A/S er vært for en telekonference i forbindelse med offentliggørelsen af årsrapporten 2012  
Feb 5, 2013 Warrant Programme - New Articles of Association  
Feb 5, 2013 Warrantordning - Nye vedtægter  
Jan 23, 2013 Veloxis Pharmaceuticals A/S etablerer warrantordning  
Jan 23, 2013 Veloxis Pharmaceuticals A/S establishes a new Warrant Programme  
Jan 3, 2013 Veloxis' Phase 3 Trial of LCP-Tacro in Stable Kidney Transplant Patients Published Online in the American Journal of Transplantation  
Jan 3, 2013 Veloxis' Phase 3 Trial of LCP-Tacro in Stable Kidney Transplant Patients Published Online in the American Journal of Transplantation  
Showing 1-34 of 34 Page: 1  
=add release to Briefcase